Both pharmacologic inhibition of mitogen-activated protein kinase (MEK) and small interfering RNA (siRNA) knockdown of ERK1/2 resulted in decreased levels of PD-L1 in melanoma cells resistant to BRAF inhibition [32]. Here, BRAF is linked to melanoma.